AzTrials
AzTrials

Premature InfantHiLoNCT03825835

30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants

A study testing 30% oxygen group and 60% oxygen group in people with Premature Infant and Respiratory Distress Syndrome in Premature Infant, run by University of Alberta at 14 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Preterm birth, or birth before 37 weeks' gestation, is increasingly common, occurring in 8 percent of pregnancies in Canada. Preterm birth is associated with many health complications, particularly when the birth happens before 29 weeks' gestation. Read more about this study

Who is it for?
Ages 0 to 10 minutes
What is being tested?
30% oxygen group and 60% oxygen group
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,203 participants
Where
14 sitesin 2 countries
Study dates
27 Jun 2022to 30 Dec 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 10 minutes
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Infants born at 23 0/7 weeks to 28 6/7 weeks' gestational age who will receive full resuscitation and are without major congenital abnormalities

Who cannot join

  • Infants who are outborn - initial resuscitation not performed at the study centre
  • Infants who are not born within the eligible gestational age range- this trial is specific to preterm infants
  • Infants who are born with a major congenital abnormality- congenital abnormalities may affect oxygenation or neurodevelopmental outcomes
  • Infants who will not receive full resuscitation at birth- these infants will not receive resuscitation

Trial locations and contacts

14 sites in 2 countries.

14 sites in 2 countries

Canada13 sites
  • Foothills Hospital

    Calgary, Alberta

  • Royal Alexandra Hospital

    Edmonton, Alberta, T5H 3V9

  • Newborn Health - IWK Health Centre

    Halifax, Nova Scotia

  • Neonatal Intensive Care Unit - Hamilton Health Sciences

    Hamilton, Ontario, L8S 4K1

  • McGill Univeristy

    Montreal, Quebec

  • CHEO

    Ottawa, Ontario

  • Chu University Laval

    Québec, Quebec

  • Université de Sherbrooke

    Sherbrooke, Quebec, J1N 3C6

  • Janeway Children's Health and Rehabilitation Centre

    St. John's, Newfoundland and Labrador, A1B 3V6

  • Neonatal Intensive Care Unit - Mount Sinai Hospital

    Toronto, Ontario

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario

  • BC Children

    Vancouver, British Colubia

  • Health Sciences

    Winnipeg, Manitoba

Other trials in Canada

Ireland1 site
  • University College Cork

    Cork

Other trials in Ireland

About this study

Official title: Does the Use of Higher Versus Lower Oxygen Concentration Improve Neurodevelopmental Outcomes at 18-24 Months in Very Low Birthweight Infants - The HiLo-Trial

Preterm birth, or birth before 37 weeks' gestation, is increasingly common, occurring in 8 percent of pregnancies in Canada. Preterm birth is associated with many health complications, particularly when the birth happens before 29 weeks' gestation. At this gestational age, the lungs are not fully developed and it is not uncommon for infants to have problems breathing at the time of birth. One complication that can arise is when an infant stops breathing and needs to be resuscitated. When preterm babies need to be resuscitated doctors must take special care because of the small infant size and the immaturity of the brain and lungs. Oxygen is used to resuscitate babies who need it, but unfortunately there is disagreement about the best oxygen concentration to use. Oxygen concentration is important because both too much and too little oxygen can cause brain injury. This research aims to fill this knowledge gap by participating in an international clinical trial to compare the effects of resuscitating babies less than 29 weeks' gestational age with either a low oxygen concentration or a high oxygen concentration. The oxygen concentrations have been selected using the best available knowledge.

This will be a cluster randomized trial where each participating hospital will be randomized to either 30 or 60 percent oxygen for the recruitment of 30 infants, and afterwards randomized to the other group for the recruitment of another 30 infants. After the trial, the investigator will determine whether the babies resuscitated with low oxygen or those resuscitated with high oxygen have better survival and long-term health outcomes. This research fills a critical knowledge gap in the care of extremely preterm babies and will impact their survival both here in Canada and internationally.

Read the detailed description

Purpose: Over the last 10 years, recommendations regarding the ideal level of oxygen for resuscitation in preterm infants have changed from 100 percent, down to low levels of oxygen (<30 percent), up to moderate concentration (30-65 percent). In addition, in 2010, oxygen saturation targeting was recommended as standard of care and this contributed to a change in clinical practice as clinicians were more likely and comfortable to start resuscitation at either 21percent (room air) or titrated levels of oxygen such as 30-40 percent. When the guidelines were again revised in 2015, the International Liaison Committee on Resuscitation (ILCOR) acknowledged that a critical knowledge gap continued to exist for the resuscitation of the preterm infants <37 weeks, highlighting the need to provide more concrete guidelines. This leaves clinicians in a challenging position. Despite the advances that have been achieved in perinatal and neonatal care, neonates are still vulnerable to the consequences of the oxidative effects from hyperoxia as well as the deleterious effects from hypoxia. A large, multi-centre international trial of sufficient sample size that is powered to look at safety outcomes such as mortality and adverse neurodevelopmental outcomes is required to provide the necessary evidenced to guide clinical practice with confidence.

Hypothesis: the null hypothesis for this study is that the incidence of mortality or abnormal neurodevelopmental outcomes at 24+/- 6 months corrected age will be no different by using either higher initial oxygen concentration of 60 percent compared to using lower initial oxygen concentration of 30 percent for resuscitation of preterm infants of 23 0/7- 28 6/7 weeks gestation.

Justification:

The use of supplementary oxygen may be crucial, but also potentially detrimental to premature infants at birth. High oxygen levels may lead to organ damage through oxidative stress, while low oxygen levels may lead to increased mortality. Excess oxygen exposure during the early post-birth period is associated with many complications and morbidities of preterm birth. Preterm infants have lower levels of anti-oxidant pathways consistent with their expected fetal environment of low oxygen exposure. Excess of oxygen free-radicals in infants intrinsically deficient in enzymatic antioxidants and non-enzymatic antioxidants may contribute to these morbidities. Pulmonary oxygen toxicity, through the generation of reactive oxygen and nitrogen species in excess of antioxidant defenses, is believed to be a major contributor to the development of bronchopulmonary dysplasia (BPD). Using lower oxygen concentrations at birth results in decreased oxidative stress markers and a decrease risk of developing BPD compared to higher oxygen concentrations. Other organs that may be damaged by such oxidative stress include kidneys, myocardium and the retina.

There is equally growing evidence that using lower oxygen concentrations will lead to lower oxygen saturation levels and bradycardia, which may lead to increased rates of mortality in this vulnerable group of infants. An individual patient analysis of clinical trials reported that 46% of preterm infants resuscitated with initial low oxygen concentration did not reach SpO2 of 80% at 5 min. This was associated with increased risk of major intraventricular hemorrhage (IVH), and an almost five times higher risk of death in this vulnerable group of infants. These data provide a warning note for the use of higher vs. lower initial oxygen concentration during delivery room resuscitation. As the investigator proceed in determining a safe range for resuscitation of ELBW/ELGA infants, it is highly likely that the optimum level of oxygen concentration is between the two extremes of 21 percent and 100 percent.

Objectives: To determine whether initial resuscitation of preterm neonates with 60 percent versus 30 percent oxygen results in better neurodevelopmental outcomes at 24+/- 6 months.

Research Method/Procedures: This will be a cluster crossover design, unmasked randomized controlled trial (RCT) comparing two oxygen concentrations at initiation of resuscitation. Infants will be placed on the resuscitation table with the initial steps of resuscitation carried out as per standard of care at each centre which usually follows current resuscitation guidelines. All centres will make every effort to establish adequate lung expansion using CPAP or positive pressure ventilation as needed. Enrolled infants will have a pulse oximeter sensor placed on the right arm in the first minute of life. Their resuscitation will be initiated with an oxygen concentration of 30 or 60 percent depending on the randomization sequence at the centre at the given time. Infants in the 30 percent group will remain in 30 percent oxygen until 5 min of age unless the infant's heart rate (HR) remains 100/min or less and does not show a tendency towards progressive increase before reaching 5 min of age or infant needs chest compression and/or epinephrine. No alteration in oxygen concentration will be made for an infant who is responding to resuscitation efforts with HR progressively increasing as minutes go by. At 5 min of age, the clinical team will assess oxygen saturation. If the saturation is less than 85 percent, oxygen should be increased by 10-20 percent every 60 sec to achieve saturations of 85 percent or greater or a saturation of 90-95 percent at 10 min of age. If saturations are greater than 95 percent at or before 5 min of age, oxygen should be decreased stepwise (every 60 sec) with an aim to maintain saturations of 85 percent or greater during 5-10 min of age or 90-95 percent at and beyond 10 min of age. The procedure for infants in the 60 percent group will be identical. The intervention duration for the trial will be the first 5 min after birth followed by initial monitoring/action for the next 5 min where titration in oxygen concentration will be made to achieve stability making a total of 10 min for study intervention. Titration of oxygen before 5 min after birth will only be made if the infant remains bradycardic (HR less than 100) and does not show a tendency towards a sustained increase in HR or if the oxygen saturation exceeds 95 percent. If the infant does not respond to ventilation with increasing HR in the first 5 min after birth, steps to ensure effective ventilation should be done before oxygen is titrated.

Plan for Data Analysis: Generalized linear mixed model with binary outcome and maximum likelihood estimate will be used to evaluate the effect of an oxygen concentration on the primary outcome (as a composite at 24+/- 6 months corrected age of all-cause mortality or the presence of a major neurodevelopmental outcome). To account for cluster crossover design of the study, effects of centers (clusters) and a period (oxygen concentration) within center will be considered random, and effects of a period (oxygen concentration) will be entered as a fixed effect. This hierarchical model allows for the correlation of patients within periods and within clusters. The model will be adjusted for gestational age and whether or not infant required mask ventilation as potential confounding variables. Similar generalized linear mixed models will be performed to evaluate the effect of group on secondary outcomes. In addition, three subgroup analysis will be performed: i) Gestational age will be categorized into 2 categories: 23+0- 25+6 vs. 26+0-28+6 weeks; ii) Breathing support will be categorized by infants supported only with CPAP vs. received mask ventilation; iii) Sex/Gender will be categorized into 2 categories: female vs. male. For subgroup analysis baseline characteristics will be compared using linear and generalized linear mixed models. Sensitivity analysis will be performed to analyze the missing data; however, a very low number of missing values are expected due to the design of the study.

Being tested
30% oxygen group, 60% oxygen group
Keywords
Delivery Room, Resuscitation, Premature Infant, Oxygen
Medical subject headings
Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 30% oxygen groupDrug

    Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.

    Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.

  • 60% oxygen groupDrug

    Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age.

    Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.

Study groups in NCT03825835
Study groupRoleWhat they receive
30% groupActive comparatorInfants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age. Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.
Receives: Drug: 30% oxygen group
60% groupExperimentalInfants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is <85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age. Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.
Receives: Drug: 60% oxygen group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of participants with composite outcome of all-cause mortality or the presence of a major neurodevelopmental outcomes

    Defined as any one of the following: Mortality or (i) cerebral palsy with an inability to walk unassisted; (ii) major developmental delay involving cognition or language; or (iii) visual (cannot fixate/legally blind, or corrected acuity < 6/60 in both eyes) or hearing impairment (requiring a hearing aid or cochlear implants).

    Measured: 24+/- 6 months corrected age

Secondary outcomes (19)
  1. Number of intubation in the delivery room

    Number of infants intubated in the delivery room

    Measured: first 15 minutes after birth

  2. Death in the Neonatal Intensive Care Unit

    Number of infants died after admission in the Neonatal Intensive Care Unit

    Measured: During admission in the Neonatal Intensive Care Unit; no exact time frame can be given as this can happen after 1 day, 1 week, 1 months or up to 2-3 month. again deepening on gestational age and policy for transferring infants at participating centres.

  3. Number of participants who died in the delivery room

    Number of infants died in the delivery room during resuscitation

    Measured: During resuscitation in the delivery room; for lay people: this time frame might be 10min or 1-3 hours, depending on the approaching each participating hospital

  4. Number of participants with severe brain injury on cranial ultrasound

    Severe grade 3 and 4 intraventricular or intraparenchymal hemorrhage according to Papile [44], periventricular leukomalacia, or ventriculomegaly based on neuroimaging studies (timing and frequency of imaging based on local site practices)

    Measured: During NICU admission (up to 6 months)

  5. Number of participants with severe retinopathy of prematurity stage 3 or higher

    As defined in the International Classification of ROP and/or ROP treated with laser, cryo-therapy, or intraocular injection therapy

    Measured: During NICU admission (up to 6 months)

  6. Number of participants with necrotizing enterocolitis

    Defined as modified Bell's criteria stage 2 or greater

    Measured: During NICU admission (up to 6 months)

  7. Number of participants with hearing loss

    Audiometry will be performed to assess the presence or absence of severe hearing loss.

    Measured: 24+/- 6 months of age

  8. Number of participants with blindness

    Blindness will be defined as a corrected visual acuity of <20/200.

    Measured: 24+/- 6 months of age

  9. Number of participants with mortality

    All cause mortality from birth until follow-up at 24+/- 6 months of age

    Measured: From birth up to 24+/- 6 months of age

  10. Number of participants with cerebral palsy with an inability to walk unassisted

    Defined as cerebral palsy with an inability to walk unassisted

    Measured: 24+/- 6 months of age

  11. Number of participants with bronchopulmonary dysplasia at 36 weeks corrected age

    Defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal cannula)

    Measured: At 36 weeks corrected age

  12. Number of participants with bronchopulmonary dysplasia at 40 weeks corrected age

    Defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal cannula)

    Measured: At 40 weeks corrected age

  13. Total duration of mechanical ventilation via an endotracheal tube in days

    Days of receiving mechanical ventilation

    Measured: Days during NICU Admission (up to 6 months)

  14. Number of participants discharged home on oxygen

    Infants who are discharged home with oxygen

    Measured: At NICU Discharge

  15. Duration of any positive pressure respiratory support in days

    Defined as (invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pres- sure, nasal intermittent positive pressure ventila- tion, or non-invasive neural assist ventilation or non-invasive high frequency ventilation, or high- flow nasal canula) in days

    Measured: Days during NICU Admission (up to 6 months)

  16. Duration of supplemental oxygen in days

    Number of days the infant receives any supplemental oxygen

    Measured: Days during NICU Admission (up to 6 months)

  17. Length of hospital stay in days

    number of days the infants I admitted in the nICU

    Measured: Days from birth to discharge (up to 6 months)

  18. Z-scores for weight, length, head circumference, and body mass index

    we will calculate Z-scores for weight, length, head circumference, and body mass index

    Measured: At 36 weeks' corrected age

  19. Differences in oxygen saturation in percentage

    we will compare the oxygen saturation in both groups

    Measured: At 3, 5, and 10 min of age after birth

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Jan 2019
  2. Study start27 Jun 2022
  3. Primary completion30 Sep 2028 (estimated)
  4. Study completion30 Dec 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
1,203 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03825835
Sponsor's protocol ID
Pro00083931
Acronym
HiLo
Status last verified
Oct 2026
First submitted
25 Jan 2019
Last updated
5 Oct 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The data will be included in a prospectively planned IPD, which is called PROMOTION Other researchers can email the PI for more information at georg.schmoelzer@me.com Study protocol: https://link.springer.com/article/10.1186/s13063-024-08080-2

Publications

  • Schmolzer GM, Asztalos EV, Beltempo M, Boix H, Dempsey E, El-Naggar W, Finer NN, Hudson JA, Mukerji A, Law BHY, Yaskina M, Shah PS, Sheta A, Soraisham A, Tarnow-Mordi W, Vento M; behalf of the HiLo trial collaborators. Does the use of higher versus lower oxygen concentration improve neurodevelopmental outcomes at 18-24 months in very low birthweight infants? Trials. 2024 Apr 4;25(1):237. doi: 10.1186/s13063-024-08080-2.

    PubMed 38576007

Questions about this trial

What is this clinical trial studying?

A study testing 30% oxygen group and 60% oxygen group in people with Premature Infant and Respiratory Distress Syndrome in Premature Infant, run by University of Alberta at 14 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 5 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in Canada, Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of participants with composite outcome of all-cause mortality or the presence of a major neurodevelopmental outcomes (time frame: 24+/- 6 months corrected age). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03825835, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in